Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Clinical trial NCT04916860 · UNKNOWN

Trial details

NCT number: NCT04916860
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: UNKNOWN
Phase: Not Applicable
Study type: INTERVENTIONAL

SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Start date: 2021-01-27
Primary completion: 2023-01-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.